In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Codexis (CDXS – Research Report). The company’s shares closed yesterday at $3.61.
According to TipRanks, Hewitt is an analyst with an average return of -2.8% and a 46.76% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Avid Bioservices, BioLife Solutions, and Apyx Medical.
Codexis has an analyst consensus of Strong Buy, with a price target consensus of $6.75, which is an 86.98% upside from current levels. In a report released on May 3, Benchmark Co. also maintained a Buy rating on the stock with a $9.00 price target.
The company has a one-year high of $4.91 and a one-year low of $1.45. Currently, Codexis has an average volume of 603.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Codexis (CDXS) Company Description:
Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. The firm operates through the following segments: Performance Enzymes and Novel Biotherapeutics. Its technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients fine chemicals, agrochemicals, food ingredients, detergents and biofuels. The company was founded in January 2002 and is headquartered in Redwood City, CA.
